Cargando…

Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Objective: To evaluate different targeted anticancer agents for patients with advanced or unresectable hepatocellular carcinoma (HCC) based on network meta-analysis. Methods: Literature retrieval was conducted in globally recognized databases, namely, MEDLINE, PMC, EMBASE and Cochrane Central to fin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Tao, Liu, Pengpeng, Yang, Jian, Wu, Ping, Chen, Baiyang, Liu, Zhisu, Li, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746130/ https://www.ncbi.nlm.nih.gov/pubmed/31528232 http://dx.doi.org/10.7150/jca.32828

Ejemplares similares

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Identifying the superior antibiotic prophylaxis strategy for breast surgery: A network meta-analysis
por: Guo, Tao, et al.
Publicado: (2019)

Identification of 13 Key Genes Correlated With Progression and Prognosis in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis
por: Gu, Yang, et al.
Publicado: (2020)

A novel microRNA miR-MTCO3P38 inhibits malignant progression via STAT3/PTTG1/MYC in hepatocellular carcinoma
por: Guo, Deliang, et al.
Publicado: (2021)

Evaluation of different antibiotic prophylaxis strategies for hepatectomy: A network meta-analysis
por: Guo, Tao, et al.
Publicado: (2019)

Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma
por: Ma, Zhili, et al.
Publicado: (2019)

Up-regulation of CDK16 by multiple mechanisms in hepatocellular carcinoma promotes tumor progression
por: Wang, Yitao, et al.
Publicado: (2017)

Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
por: Zhang, Zhenzhen, et al.
Publicado: (2022)

Retraction Note: Up-regulation of CDK16 by multiple mechanisms in hepatocellular carcinoma promotes tumor progression
por: Wang, Yitao, et al.
Publicado: (2019)

Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis
por: Long, Jiaye, et al.
Publicado: (2023)

The clinical effects of antibiotic prophylaxis for hysteroscopic procedures: A meta-analysis
por: Guo, Tao, et al.
Publicado: (2019)

YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an m6A-Dependent Manner
por: Tan, Chunzhong, et al.
Publicado: (2022)

Cancer cell membrane-camouflaged MOF nanoparticles for a potent dihydroartemisinin-based hepatocellular carcinoma therapy
por: Xiao, Yusha, et al.
Publicado: (2020)

A Novel End-to-End Biliary-to-Biliary Anastomosis Technique for Iatrogenic Bile Duct Injury of Strasberg-Bismuth E1-4 Treatment: A Retrospective Study and in vivo Assessment
por: Ma, Dong, et al.
Publicado: (2021)

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
por: Liu, Kun, et al.
Publicado: (2023)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
por: Kumar, Shashank, et al.
Publicado: (2023)

FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway
por: Ma, Dong, et al.
Publicado: (2023)

Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis
por: Chen, Xin-Long, et al.
Publicado: (2022)

Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents
por: Chen, Shiguang, et al.
Publicado: (2018)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
por: Sun, Weijing, et al.
Publicado: (2018)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Systemic treatment for unresectable hepatocellular carcinoma
por: Leowattana, Wattana, et al.
Publicado: (2023)

The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma
por: Chang, Lei, et al.
Publicado: (2016)

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
por: Jiang, Nan, et al.
Publicado: (2023)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis
por: Xie, Hui, et al.
Publicado: (2017)

Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
por: Sun, Hui-Chuan, et al.
Publicado: (2021)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Junguo, et al.
Publicado: (2022)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1
por: Liu, Pengpeng, et al.
Publicado: (2022)

Identifying the optimal criteria of radiotherapeutic parameters for patients with unresectable locally advanced hepatocellular carcinoma
por: Son, Seok Hyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l69ftq03re2ccq61i95muqr9ad